---

Brought to you by RivalSense - an AI tool for monitoring any company.

RivalSense tracks the most important product launches, fundraising news, partnerships, hiring activities, pricing changes, tech news, vendors, corporate filings, media mentions, and other developments of companies you're following 💡

---

Rīgas Austrumu klīniskā universitātes slimnīca

🌎 aslimnica.lv

Rīgas Austrumu klīniskā universitātes slimnīca is the largest healthcare institution in Latvia, offering a wide range of diagnostic and treatment options. It comprises five hospitals, including 'Gaiļezers', 'Latvijas Onkoloģijas centrs', 'Biķernieki', 'Latvijas Infektoloģijas centrs', and 'Tuberkulozes un plaušu slimību centrs', as well as a Pathology center.

---

Updates as of Sep 30, 2024

• Vadims Beļuns will become the fourth board member of Rīgas Austrumu klīniskā universitātes slimnīca responsible for diagnostics and medical support services management starting November 1, 2024.
• Rīgas Austrumu klīniskā universitātes slimnīca has launched three innovative pilot projects to improve targeted and personalized oncology diagnostics and treatment, supported by the National Health Service's Health Care Service Model Development Laboratory.
• Rīgas Austrumu klīniskā universitātes slimnīca announced an open competition for road repair and asphalting works in their properties with a submission deadline of October 21, 2024.
• On September 25-27, Rīgas Austrumu klīniskā universitātes slimnīca hosted the EuCanScreen project launch conference, discussing the establishment of an international regional Mammography Training Center and the implementation of the Dutch Expert Centre for Screening's quality program in Latvia.
• Rīgas Austrumu klīniskā universitātes slimnīca will start a major expansion project in January 2024 to build a new combined infection, tuberculosis, and lung building in Riga, aiming to centralize services and improve patient experience by early 2027.

---

Did you find it useful?

If you liked this report, consider following your own companies of interest. Receive weekly insights directly to your inbox using RivalSense.